Drug Information
Drug (ID: DG01713) and It's Reported Resistant Information
Name |
Azacitidine/Sorafenib
|
||||
---|---|---|---|---|---|
Synonyms |
Azacitidine/Sorafenib
Click to Show/Hide
|
||||
Target | . | NOUNIPROTAC | [1] |
Type(s) of Resistant Mechanism of This Drug
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Acute myeloid leukemia [ICD-11: 2A60]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Receptor-type tyrosine-protein kinase FLT3 (FLT3) | [1] | |||
Molecule Alteration | IF-insertion | p.Y599_D600insSTDNEYFYVDFREYEY (c.1797_1798insAGCACAGACAACGAGTATTTTTATGTAGACTTTAGGGAGTATGAGTAT) |
||
Sensitive Disease | Acute myeloid leukemia [ICD-11: 2A60.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Bone marrow | N.A. | ||
Mechanism Description | The if-insertion p.Y599_D600insSTDNEYFYVDFREYEY (c.1797_1798insAGCACAGACAACGAGTATTTTTATGTAGACTTTAGGGAGTATGAGTAT) in gene FLT3 cause the sensitivity of Azacitidine + Sorafenib by unusual activation of pro-survival pathway. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.